Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash from Financing Activities (2016 - 2025)

Immucell (ICCC) has disclosed Cash from Financing Activities for 16 consecutive years, with -$337689.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 110.51% year-over-year to -$337689.0, compared with a TTM value of -$668918.0 through Sep 2025, down 127.73%, and an annual FY2024 reading of $2.9 million, up 64.6% over the prior year.
  • Cash from Financing Activities was -$337689.0 for Q3 2025 at Immucell, down from -$76448.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $4.0 million in Q2 2021 and bottomed at -$403647.0 in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $463654.8, with a median of -$176425.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 528.91% in 2021, then surged 1114.39% in 2022.
  • Year by year, Cash from Financing Activities stood at -$194905.0 in 2021, then fell by 27.35% to -$248209.0 in 2022, then dropped by 29.5% to -$321433.0 in 2023, then skyrocketed by 146.31% to $148866.0 in 2024, then tumbled by 326.84% to -$337689.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for ICCC at -$337689.0 in Q3 2025, -$76448.0 in Q2 2025, and -$403647.0 in Q1 2025.